Synstatin, a mimetic peptide, inhibits the signaling complex formation between SDC-1, IGF1R, and integrin αvβ3 and attenuates HS-dependent angiogenic VEGF and FGF2 signaling, and blocks tumor angiogenesis in vivo [149,150]. Here, SDC1 is linked to neoplasm.